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Abstract
Context: Depression is associated with increased mortality, but it is unclear if this relationship is dose-dependent and if it
can be modified by treatment with antidepressants.
Objective: To determine if (1) the association between depression and mortality is independent of other common potential
causes of death in later life, (2) there is a dose-response relationship between increasing severity of depression and mortality
rates, and (3) the use of antidepressant drugs reduces mortality rates.
Methods: Cohort study of 5,276 community-dwelling men aged 68–88 years living in Perth, Australia. We used the Geriatric
Depression Scale 15-items (GDS-15) to ascertain the presence and severity of depression. GDS-15$7 indicates the presence
of clinically significant depression. Men were also grouped according to the severity of symptoms: ‘‘no symptoms’’ (GDS-
15=0), ‘‘questionable’’ (1#GDS-15#4), ‘‘mild to moderate’’ (5#GDS-15#9), and ‘‘severe’’ (GDS-15$10). Participants listed all
medications used regularly. We used the Western Australian Data Linkage System to monitor mortality.
Results: There were 883 deaths between the study assessment and the 30th June 2008 (mean follow-up of participants:
6.061.1 years). The adjusted mortality hazard (MH) of men with clinically significant depression was 1.98 (95%CI=1.61–
2.43), and increased with the severity of symptoms: 1.39 (95%CI=1.13–1.71) for questionable, 2.71 (95%CI=2.13–3.46) for
mild/moderate, and 3.32 (95%CI: 2.31–4.78) for severe depression. The use of antidepressants increased MH (HR=1.31,
95%CI=1.02–1.68). Compared with men who were not depressed and were not taking antidepressants, MH increased from
1.22 (95%CI=0.91–1.63) for men with no depression who were using antidepressants to 1.85 (95%CI=1.47–2.32) for
participants who were depressed but were not using antidepressants, and 2.97 (95%CI=1.94–4.54) for those who were
depressed and were using antidepressants. All analyses were adjusted for age, educational attainment, migrant status,
physical activity, smoking and alcohol use and the Charlson comorbidity index.
Conclusions: The mortality associated with depression increases with the severity of depressive symptoms and is largely
independent of comorbid conditions. The use of antidepressants does not reduce the mortality rates of older men with
persistent symptoms of depression.
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Introduction
Depression is a common and disabling condition that affects 1
in 6 people over the course of their lives [1,2]. Its presence has
been associated with deteriorating physical health [3] and
increased mortality [4,5,6,7,8]. although the mechanisms linking
depression to these poor health outcomes remain unclear.
Smoking, obesity and physical inactivity are more prevalent
amongst depressed than non-depressed adults, and may explain, at
least in part, this excess in morbidity and mortality [9,10,11,12].
There is a similarly higher prevalence of hypertension and
diabetes amongst people with depression [13,14], which together
with deficient immune and inflammatory responses [15], may
contribute to further increments in ill health and death.
Antidepressant treatment could conceivably minimise the
negative health implications associated with depression by acting
directly on the physiological pathways that leads to greater
morbidity and mortality or, indirectly, by improving compliance
with the management of comorbid disorders and facilitating a
healthier lifestyle [16,17]. A secondary analysis of the Enhancing
Recovery in Coronary Heart Disease (ENRICHD) study showed
that treatment with selective serotonin reuptake inhibitors (SSRIs)
reduces subsequent cardiovascular morbidity and mortality in
adults who were depressed after they had a heart attack [18].
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incidence rate ratio of colorectal cancer over a period of 5 years in
a nested case-control study [19], although there are lingering
concerns about the potential carcinogenic effects of some
antidepressants [20,21,22]. In addition, there is evidence from
ecological studies that the rise in the use of antidepressants has
been associated with a concomitant decline in the number of
suicides in the community [23], but it is debatable if the link
between antidepressant sales and death by suicide is truly causal
[24].
Results from the Three City Study (3C) [25] suggest that
treatment with antidepressants may not necessarily reduce the risk
of death in older adults with depression; in fact, the opposite may
be true. The 3C was a longitudinal study that followed 7,363
French men and women aged 65 years or over for 4 years.
Participants were screened with the Centre for Epidemiological
Studies Depression Scale (CES-D) and interviewed with the Mini
International Neuropsychiatric Interview (MINI) to establish the
diagnosis of major depression according to DSM-IV criteria.
Older adults with a CES-D score between 16 and 22 (inclusive)
who did not meet criteria for major depression were considered to
have ‘mild depression’, whereas participants with major depression
or a CES-D score of 23 or more were considered to have ‘severe
depression’. Men and women with severe depression not treated
with antidepressants had an 80% higher mortality hazard than
participants with no depression who were not using antidepres-
sants. The mortality hazard increased for men, but not women,
with mild (hazard ratio [HR]=2.8, 95% confidence interval
[CI]=1.0–7.7) and severe depression treated with antidepressants
(HR=5.3, 95%CI=2.7–10.5). However, the number of deaths in
this investigation was small (215 men and 165 women) and the
study lacked power to establish unequivocally the role of
antidepressants on mortality.
We designed the present study to determine: (1) whether older
men with clinically significant depressive symptoms have increased
mortality, (2) whether the association between depression and
mortality in older men is independent of other common potential
causes of mortality in later life, (3) whether there is a dose-response
relationship between increasing severity of depression and
mortality rates, (4) whether the severity of depression influences
the cause of death, and (5) whether the use of antidepressant drugs
is associated with a decline in mortality rates.
Methods
Study design and participants
This study used a population-based sample of older men living
in the Perth metropolitan area that represents the inception cohort
of the Health In Men Study (HIMS). Details regarding the
recruitment of participants have been described elsewhere [26].
During the years 2001–2004 those men who were still alive were
contacted and invited to complete a follow-up assessment. We
excluded from the present study men with a recorded history of
dementia, drug abuse or dependence, psychosis or depression
before 2001 – their exclusion aimed to minimize confounding
associated with the past use of psychotropic agents, in particular
antipsychotics [27]. These diagnoses were established by means of
the Western Australian Data Linkage System (WADLS), which
connects together all death records, acute hospital admissions,
hospital movements, cancer registry, as well as psychiatric
outpatient contacts for all residents of Western Australia since
1980 [28,29]. This report refers to 5,276 subjects who were eligible
and consented to follow-up. The Human Research Ethics
Committee of the University of Western Australia approved the
study protocol and all subjects provided written informed consent
to participate.
Outcome of interest
All cause mortality was the primary outcome of interest of the
study. The Western Australian Data Linkage System (WADLS)
retrieved information from the Australian Bureau of Statistics that
reported the cause(s) of death of participants according to the
ICD-10 (http://www.abs.gov.au/ausstats/abs@.nsf/mf/3303.0).
Explanatory variables
Participants were asked to complete the 15-item Geriatric
Depression Scale (GDS-15) at the baseline assessment and, a priori,
those with a total score of 7 or more were considered to display
clinically significant depressive symptoms at the time of assess-
ment. This relatively high cut-point was chosen to ensure high
specificity for the diagnosis of depression in this sample [30]. We
also used previously published data to guide the grouping of
participants according to the severity of depressive symptoms: ‘no’
(GDS-15 total score=0), ‘questionable’ (GDS-15 total score 1 to
4), ‘mild to moderate’ (GDS-15 total score 5 to 9) and ‘severe’
depression (GDS-15 total score 10 to 15) [30].
We calculated the age of participants as the difference in days
between the date of the assessment and their date of birth divided
by 365.25. In addition, men reported the highest level of education
achieved (completed or not high school) and their country of birth.
Participants were also asked whether they were currently smoking
cigarettes, cigars or a pipe regularly (possible answers: every day/
not every day/not at all). Men who answered ‘every day’ or ‘not
every day’ were classified as current smokers.
At the time of assessment, we asked men if they had been told
by a doctor during the previous 5 years that they had arthritis,
cancer (colon, prostate or melanoma), a cardiovascular illness
(angina, myocardial infarction or stroke), diabetes, hypertension,
or pulmonary diseases (chronic bronchitis, emphysema or asthma).
We then used administrative medical information from WADLS
during the 10 years prior to assessment at HIMS to calculate the
Charlson index and determine the presence of significant medical
comorbidity in our sample [31]. The index takes into account 17
common medical conditions that predict 1-year mortality:
myocardial infarction, congestive heart failure, peripheral arterial
disease, cerebrovascular disease, dementia, chronic pulmonary
disease, connective tissue disease, ulcer disease, liver disease,
diabetes (including diabetes with end organ damage), hemiplegia,
renal disease, leukemia, lymphoma, other tumours, metastatic
tumours and AIDS. Charlson and colleagues used adjusted
relative risks to assign integer weights to these conditions within
a composite index score that ranges from 0 to 37. Coding
algorithms to define comorbidities followed the procedures
described by Quan et al. [32] and scores were calculated using
Stagg’s Charlson’s index Stata 9.2 routine (StataCorp, College
Station, Texas). We stratified scores, as per usual practice [33], to
reflect the increasing severity of comorbidity associated with the
index.
Finally, we asked participants to list all medications they were
consuming on a regular basis at the time of assessment at HIMS.
We coded the medications according to the World Health
Organisation Standard Classification of Medications [34]. Only
information about the use of antidepressants was retrieved for this
study.
Statistical analyses
Data were analyzed with the statistical package Stata release
10.0 (StataCorp, College Station, TX). We used 262 tables to
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and non-participants. We identified potential confounders of the
association between depression and mortality by comparing men
with and without depression for the distribution of relevant
demographic, lifestyle and clinical variables. After completing the
preliminary univariate analysis, Cox proportional-hazards regres-
sion models were applied to estimate the adjusted mortality hazard
associated with prevalent depression. We progressively included
demographic, lifestyle and clinical variables, and retained in the
final model only those that contributed significantly to mortality
(age was entered in the adjusted models as a continuous variable).
Depression was included in the models as a binary (GDS$7, yes/
no) or ordinal variable (low, questionable, mild/moderate and
severe depressive symptoms).
We grouped participants into four categories to investigate the
interaction between antidepressant use, depression and mortality:
no depression and no antidepressants, no depression with
antidepressants, depression and no antidepressants, and depression
with antidepressants. Taking the first group as reference, we used
Cox regression models to assess the association between group
membership and mortality, and adjusted all analyses for the
relevant demographic, lifestyle and clinical risk factors.
Finally, we used a 262 tables to calculate the absolute risk
increase as well as the number needed to harm associated with the
use of antidepressant treatment of older men with depression.
Ninety-five percent confidence intervals (95%CI) were estimated
for the risk ratio, hazard ratio, absolute risk increase, and number
needed to harm. Alpha was set at 5% and all probability tests
reported are two-tailed.
We estimated that a study with 5,276 participants would have
80% power to declare as significant an adjusted mortality hazard
ratio of 1.25 or greater, as estimated by the Stata command
stpower cox.
Results
Figure 1 shows the flow of participants from invitation to
inclusion in this study. The age of participating men ranged from
68 to 88 years (mean6SD: 76.763.8) and 297 (5.6%) of them
displayed clinically significant symptoms of depression at the time
of assessment (i.e., GDS-15$7). Participants with depression were
older than non-depressed men (t=2.74, df=5274, p=0.006),
although the age difference between the groups was small
(77.363.8 vs 76.764.0, respectively). Older men with depression
had greater odds of having been born overseas or having ever
smoked, drinking 28 or more standard drinks of alcohol over a
usual one-week period, having a body mass index greater than 25
(i.e., overweight or obese) and showing evidence of greater medical
morbidity. In contrast, physical activity (vigorous and non-
vigorous) and higher education were associated with reduced
odds of depression. Table 1 summarises the demographic, lifestyle
and medical characteristics of participants with and without
depression.
There were 883 deaths between the study assessment and the
30
th June 2008 (mean follow-up of participants: 6.061.1 years).
The characteristics of men who died during the follow up period
are described in table 2. The relative risk of death amongst men
with clinically significant depression was 2.26 (95%CI: 1.91–2.53)
compared with non-depressed men. The risk of death was higher
in the older age group, as well as amongst men who had not
completed high school education, who had ever smoked, drank
more than 28 standard drinks of alcohol per week, did not engage
in regular vigorous physical activity, or who had cancer,
cardiovascular disease, diabetes and diseases of the lungs. The
risk of death increased with the severity of clinical comorbidity, as
measured by the Charlson index.
We used Cox regression to determine if the increased risk of
death associated with depression could be explained by other
measured factors. The crude rate ratio of death associated with
depression was 2.58 (95%CI: 2.11–3.17), and was reduced to 2.40
(95%CI: 1.95–2.94) after the analyses were adjusted for age,
educational attainment, and migrant status. Additional adjust-
ments including current smoking (rate ratio: 2.32, 95%CI: 1.89–
2.85), and self-reported comorbidities (rate ratio: 2.07, 95%CI:
1.67–2.55) or the Charlson index (rate ratio: 1.98, 95%CI: 1.61–
2.43) showed that the excess mortality associated with depression
could not be adequately explained by these factors.
We then conducted a series of analyses to clarify if death in this
cohort was associated with the severity of depressive symptoms.
One thousand one hundred and sixty-six men reported no
depressive symptoms at assessment (total GDS-15 score=0) and
were used as the reference group in a fully adjusted Cox regression
model that included all measured demographic, lifestyle and
comorbid variables (measured by the Charlson index). Figure 2
illustrates the results of these analyses. The rate ratio of death
associated with depression increased with the severity of
symptoms: 1.39 (95%CI: 1.13–1.71) for questionable, 2.71
(95%CI: 2.13–3.46) for mild/moderate, and 3.32 (95%CI: 2.31–
4.78) for severe depression, respectively.
Table 3 summarises the most frequent causes of death
according to the severity of depressive symptoms. The commonest
cause of death amongst participants with no depressive symptoms
at the baseline assessment was cancer, whereas cardiovascular
diseases were the most prevalent contributors to the death of men
with mild to severe depressive symptoms. Posthoc analyses showed
that, compared with non-depressed participants, the hazard of
death due to cardiovascular disease increased to 1.52
(95%CI=1.10–2.11) for questionable depression, and 4.36
(95%CI=3.03–6.27) and 5.71 (95%CI=3.43–9.50) for mild/
Figure 1. The diagram shows the flow of participants from the
time of invitation to inclusion in the study.
doi:10.1371/journal.pone.0011266.g001
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adjusted for age at entry, education level, country of birth and
smoking status).
Figure 3 shows the mortality hazard of men according to
whether or not they were using antidepressants at the beginning of
the follow up period. We used as the reference group men who
showed no evidence of clinically significant depression (i.e., GDS-
15,7) and who were not taking antidepressants. The mortality
hazard ratio increased to 1.22 (95%CI=0.91–1.63) for men with
no depression who were using antidepressants, 1.85
(95%CI=1.47–2.32) for participants who were depressed but
were not using antidepressants, and 2.97 (95%CI=1.94–4.54) for
those who were depressed and were using antidepressants.
The mortality hazard associated with the interaction between
depression and antidepressant use was 1.32 (95%CI=0.76–2.30;
z=0.98, p=0.328). As the interaction between depression and
antidepressant use did not contribute to explain mortality, the
term was not included in the final explanatory model, which
showed that the independent (fully adjusted) mortality hazard
associated with depression and antidepressant use was 1.93
(95%CI=1.57–2.38; z=6.18, p,0.001) and 1.31 (95%CI=
1.02–1.68; z=2.14, p=0.032), respectively.
Table 4 summarises the most frequent causes of death amongst
these men, whereas table 5 lists the most frequent causes of death
according to the type of antidepressant used by participants. We
conducted a series of analyses to determine if depression and
antidepressants were associated with cause-specific mortality. Both
depression (HR=2.69, 95%CI=2.01–3.59; z=6.67, p,0.001)
and antidepressant use (HR=1.43, 95%CI=1.00–2.03; z=1.99,
p=0.047) were independently associated with death due to
cardiovascular disease after adjustments were made for age,
education, country of birth and smoking. Depression was also
associated with greater adjusted mortality hazard due to cancer
(HR=1.76, 95%CI=1.23–2.52; z=3.10, p=0.002), but not
antidepressants (HR=1.01, 95%CI=0.65–1.56; z=0.05,
p=0.960). No further analyses were conducted because of the
relatively small number of deaths due to other causes.
Finally, we completed sensitivity analyses to determine if the
association between depression, antidepressants and mortality had
been confounded by severity of physical illness around the time of
assessment at HIMS, such that poor physical health could have led
to depressive symptoms at HIMS and death at follow up. We
repeated the analyses described above after excluding the 22 men
who died during the first year of follow up. Clinically significant
depression (GDS-15$7) continued to be associated with increased
mortality hazard (HR=1.95, 95%CI=1.58–2.41; z=6.22,
p,0.001), as did the use of antidepressants (HR=1.30,
95%CI=1.01–1.66; z=2.04, p=0.041). We extended our sensi-
tivity analyses by excluding from the analyses all men who died
during the first 2 years of follow up (n=75). Again, we observed a
consistent increase in the mortality hazard associated with
depression (HR=1.92, 95%CI=1.54–2.39; z=5.78, p,0.001)
and antidepressant use (HR=1.30, 95%CI=1.00–1.69; z=1.98,
p=0.047). All analyses were adjusted for the factors listed in table 1.
Table 1. Demographic, lifestyle and clinical factors associated with prevalent depression.
Depressed
N=297
n( % )
Not depressed
N=4,979
n (%) Odds Ratio (95%CI)
Demographics
Completed at least
high school
106 (35.7) 2,320 (46.6) 0.63 (0.50–0.81)
Born overseas 139 (46.8) 1,951 (39.2) 1.37 (1.08–1.73)
Lifestyle
Current smoking 26 (8.7) 242 (4.9) 1.88 (1.18–2.89)
Comorbidities
Arthritis 141 (47.5) 1,629 (32.7) 1.86 (1.49–2.36)
Cancer* 63 (21.2) 692 (13.9) 1.67 (1.25–2.29)
Cardiovascular disease
# 113 (38.1) 975 (19.6) 2.52 (1.97–3.23)
Diabetes 59 (19.9) 525 (10.5) 2.10 (1.56–2.84)
Hypertension 101 (34.0) 1,482 (29.8) 1.22 (0.95–1.56)
Pulmonary diseases
$ 69 (23.2) 558 (11.2) 2.40 (1.80–3.19)
Charlson index (weighted) 0
1–2
3–4
5+
162 (54.6)
48 (16.2)
53 (17.9)
34 (11.5)
3,686 (74.0)
645 (13.0)
436 (8.8)
212 (4.3)
1
1.69 (1.21–2.36)
2.77 (2.00–3.83)
3.65 (2.46–5.42)
Antidepressants
Any 52 (17.5) 247 (5.0) 4.10 (2.88–5.67)
Tricyclic antidepressants 17 (5.7) 110 (2.2) 2.69 (1.49–4.58)
SSRIs 26 (8.8) 109 (2.2) 4.29 (2.63–6.75)
Other antidepressants 12 (4.0) 31 (0.6) 6.72 (3.11–13.62)
SSRIs=selective serotonin reuptake inhibitors.
*melanoma, colon and prostate cancer;
#angina, myocardial infarction and stroke;
$chronic bronchitis, emphysema and asthma.
doi:10.1371/journal.pone.0011266.t001
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The results of this study indicate that the 6-year adjusted
mortality hazard is twice as high for men with depression
compared with non-depressed men and that the use of
antidepressants is associated with an independent rise in mortality
of 30%. Our findings also show that the rate ratio of death
increases with the severity of depressive symptoms, and that the
causes of death of men with mild to severe depression are different
from men with no or questionable depression: cardiovascular
diseases are more prevalent amongst depressed men, whereas
cancer is slightly more frequent amongst men with no or
questionable depression. Finally, we found that the adjusted
mortality hazard of participants increased progressively according
to depression status and antidepressant use, being nearly 3 times as
high for men with depression on antidepressants compared with
non-depressed men not using antidepressants, and 1.8 for men
with depression not using antidepressants.
Before discussing the implications of our findings, we wish to
highlight some of the strengths and limitations of the study design
and place them into context. This project has the merit of having
used a well established cohort of older men for whom detailed
clinical and administrative information is available [26]. The
assessment at HIMS allowed us to collect information about the
severity of depressive symptoms and the use of antidepressants at
the time of entry into the study, whilst WADLS provided
systematic information about mortality and its causes. As moves
into and away from Western Australia are negligible in this age
group [35], WADLS was able to track the deaths that occurred in
the entire cohort during the follow up period with great accuracy.
In addition, WADLS is one of the most robust systems to monitor
the occurrence of health events in the population currently
available in the World [29], and this enabled us to ascertain the
independent contribution of depression to the mortality of older
men without having to rely on self-reported information about the
presence of various comorbid conditions. In addition, as WADLS
provides complete information on mortality for the entire
population, there was no differential loss to follow up of people
with and without depression. Nonetheless, our ascertainment of
the exposures of interest (i.e., depression and antidepressant
treatment) was limited to the starting point of the study, and we
are therefore unable to comment on the likely impact that changes
in the level of these exposures during the follow up period could
have had on mortality.
We also acknowledge that the assessment of depression was not
based on a structured clinical interview and, as a result, our data
do not allow for direct inferences to be made about the differential
6-year mortality of older men with a DSM-IV episode of major
depression, although the approach that we used has been
previously shown to have good sensitivity and specificity for the
diagnosis of major depression [30]. Another limitation of our
survey is that it was limited to men and our results may not
necessarily apply to women. Furthermore, we acknowledge that
the observational nature of the study and the inherent non-
randomised comparison of older men with depression who were or
not treated with antidepressants is subject to bias, especially
confounding by indication, whereby unmeasured factors (which
we were consequently unable to adjust for in our analyses) might
have influenced the choice of antidepressant treatment and
contributed to subsequent mortality. Finally, we attempted to
minimise the effect that significant medical morbidity at the time
of assessment could have had on the expression of depressive
symptoms [36] and mortality by repeating our analyses after the
exclusion of participants who had died during the first and second
years of follow up, and found that the results of the study were not
altered. This, together with the observation that older men with
depression seem less likely to die from cancer (a group of diseases
that is associated with high lethality), suggests that the observed
associations in our study cannot be easily dismissed as a result of
confounding and bias.
Given the characteristics of the study, we would argue that our
findings of increased mortality associated with depression in older
men are valid: they are twice as likely to die over a 6-year period as
non-depressed men. The results of previous studies investigating
the mortality of older people with depression lend further support
to our conclusions and are summarised in Table S1 (citations 50 to
62 [50–62] refer to studies listed in this table. Please see also review
by Cuijpers et al. [37]). In addition, we found a dose-response
relationship between the severity of depressive symptoms and
death in our cohort, with the mortality hazard of men with severe
depression being more than three-times higher than that of non-
depressed participants. Two studies had previously attempted to
investigate the association between the severity of depression and
death. The most recent was based on the Amsterdam Study of the
Elderly (AMSTEL) and included 1,989 people aged 65–84 years
that were followed for up to 10 years [38]. They found that
moderate and severe depression were associated with 29%
(95%CI=3%–61%) and 34% (95%CI=7%–68%) increase in
mortality hazard compared with non-depressed older people, but
were unable to demonstrate a clear dose effect of depression partly
Table 2. Demographic, lifestyle and clinical factors associated
with death during follow up.
Dead
N=883
n( % )
Alive
N=4,393
n( % )
Relative Risk
(95%CI)
Depression 105 (11.9) 192 (4.4) 2.26 (1.91–2.53)
Demographics
Age at entry, mean (sd) 78.7 (4.2) 76.3 (3.6) 2.37 (2.10–2.64)
Completed at least high school 357 (40.4) 2,069 (47.1) 0.81 (0.72–0.91)
Born overseas 341 (38.6) 1,749 (39.8) 0.95 (0.84–1.07)
Lifestyle
Current smoking 73 (8.3) 195 (4.4) 1.94 (1.45–2.58)
Comorbidities
Arthritis 322 (35.5) 1,475 (33.5) 1.08 (0.95–1.22)
Cancer* 176 (19.2) 588 (13.3) 1.42 (1.23–1.64)
Cardiovascular disease
# 269 (29.3) 8.47 (19.2) 1.57 (1.38–1.78)
Diabetes 119 (13.1) 475 (10.8) 1.19 (1.00–1.42)
Hypertension 272 (29.8) 1,332 (30.6) 0.98 (0.86–1.12)
Pulmonary diseases
$ 115 (19.7) 427 (13.2) 1.66 (1.43–1.92)
Charlson index (weighted) 0
1–2
3–4
5+
493 (55.8)
148 (16.6)
144 (16.3)
98 (11.1)
3,355 (76.4)
545 (12.4)
345 (7.9)
148 (3.4)
1
1.84 (1.51–2.27)
2.84 (2.29–3.52)
4.51 (3.43–5.92)
Antidepressants
Any
TCA
SSRIs
Other
70 (7.9)
30 (3.4)
32 (3.6)
9 (1.0)
229 (5.2)
97 (2.2)
103 (2.3)
34 (0.8)
1.57 (1.16–2.08)
1.56 (0.99–2.38)
1.57 (1.01–2.37)
1.32 (0.55–2.82)
SSRIs=selective serotonin reuptake inhibitors.
*melanoma, colon and prostate cancer;
#angina, myocardial infarction and stroke;
$chronic bronchitis, emphysema and asthma.
doi:10.1371/journal.pone.0011266.t002
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(about 4,000 people). Loss to follow up is a common problem of
longitudinal studies that we were able to minimise by using the
WADLS. The 3C study [25], which we have previously described,
found a dosage relationship between the severity of depressive
symptoms and death amongst men taking antidepressants, but not
amongst those with depression not using antidepressants, a finding
that is consistent with our own results.
We found that antidepressant treatment increases the mortality
hazard of men by 30%, and this association is independent of the
presence of clinically significant depression. However, it is possible
that non-surviving men had a more chronic and unremitting
course of illness, which may have confounded the direct effect of
antidepressants on mortality. Such an interpretation of our
findings is partly supported by the lack of association between
antidepressant use and mortality amongst men without depression,
Figure 2. Cumulative mortality hazard over time (in years) associated with the severity of depressive symptoms (adjusted for all
measured demographic and lifestyle factors as well as comorbidities listed in table 1). The groups with ‘no’, ‘questionable’, ‘mild to
moderate’ and ‘severe’ depression corresponded to GDS-15 total scores of 0 (n=1,166), 1 to 4 (n=3,465), 5 to 9 (n=533) and 10 or greater (n=112),
respectively.
doi:10.1371/journal.pone.0011266.g002
Table 3. Mortality rates (95% confidence interval) per 1,000 persons per year according to the severity of depressive symptoms at
the time of assessment.
Causes of death, n (%)
No depression*
N=110 deaths
Questionable
depression
#
N=556 deaths
Mild/moderate
depression
+
N=176 deaths
Severe depression
{
N=41 deaths
Cardiovascular diseases 6.1 (4.4–8.5) 9.2 (7.7–11.1) 25.5 (20.0–32.6) 32.4 (21.1–50.0)
Cancer 7.7 (5.7–10.3) 9.9 (8.2–11.9) 15.1 (11.2–20.4) 15.2 (8.3–28.0)
Chronic respiratory diseases 0.9 (0.4–2.0) 2.0 (1.4–3.0) 5.8 (3.5–9.6) 7.8 (3.3–18.4)
Infections 3.3 (2.1–5.1) 5.5 (4.3–7.0) 10.6 (7.4–15.3) 12.8 (6.5–25.2)
Dementia 0.3 (0.1–1.1) 1.3 (0.8–2.2) 5.5 (3.2–9.4) 6.5 (2.5–16.8)
Suicide or accidents 0.0 (0.0–0.7) 0.0 (0.0–0.3) 0 0
Other causes 0.8 (0.3–2.0) 1.2 (0.7–2.1) 1.2 (0.4–3.4) 0
Contributing causes of death for each depression group were
*135,
#723,
+243 and
{54 causes of death (i.e., death might have been attributed to more than one cause).
All rates were standardised for age (median age of 76.3 years), education, country of birth and smoking status.
doi:10.1371/journal.pone.0011266.t003
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decreases if treatment is associated with the remission of
symptoms. Heart rate variability (HRV) is one of the possible
physiological mechanisms linking depression, antidepressants and
death. There is increasing evidence that adults with depression
have reduced HRV (i.e., decrease ability to increase/decrease
heart rate according to physiological demands) and that reduced
HRV increases mortality [39,40]. Recovery from depression
(spontaneously or as a result of treatment) increases HRV [41] and
this may contribute to reduce mortality amongst adults at risk. A
recent review of this topic confirms that this is a plausible
explanation for our results [42].
It is also important to consider that the use of antidepressants
has been associated with numerous potentially harmful effects,
some of which may increase morbidity and mortality. For
example, antidepressant treatment has been linked to increased
risk of injurious and non-injurious falls in cross-sectional and
longitudinal studies [43,44], and there is some evidence that the
use of common antidepressants increases the risk bleeding in
various body systems, including the central nervous system [45], as
Figure 3. Mortality hazard of men without depression treated with antidepressants (n=247, black), men with depression not
treated with antidepressants (n=245, red), and men with depression treated with antidepressants (n=52, green) (reference group:
men with no depression not using antidepressants, n=4,732). The mortality hazard ratio associated with the use tricyclic antidepressants
(m), selective serotonin inhibitors (SSRIs)(&), other antidepressants (x) and all antidepressants combined (X) is shown in the figure. The whiskers
represent the 95% confidence interval of the mortality hazard ratio. All analyses were adjusted for the demographic and lifestyle factors, as well as the
comorbidities listed in table 1.
doi:10.1371/journal.pone.0011266.g003
Table 4. Mortality rates (95% confidence interval) per 1,000 persons per year according to depression (GDS-15$7) and
antidepressant use.
Causes of death, n (%)
No depression and no
antidepressant*
N=730 deaths
No depression with
antidepressant
#
N=48 deaths
Depression and no
antidepressant
+
N=83 deaths
Depression with
antidepressant
{
N=22 deaths
Cardiovascular diseases 9.5 (8.0–11.3) 11.9 (7.6–18.6) 22.9 (16.3–32.2) 41.8 (24.4–71.7)
Cancer 9.8 (8.2–11.6) 7.5 (4.3–13.2) 14.2 (9.3–21.73) 27.0 (13.9–52.6)
Chronic respiratory diseases 1.9 (1.3–2.8) 2.2 (0.8–6.0) 8.2 (4.5–15.0) 8.6 (2.7–27.4)
Infections 5.2 (4.1–6.5) 6.0 (3.2–11.1) 11.6 (7.2–18.7) 20.5 (9.6–43.8)
Dementia 1.4 (0.9–2.2) 1.0 (0.2–4.1) 5.1 (2.4–10.5) 8.0 (2.4–26.1)
Suicide or accidents 0.0 (0.0–0.3) 0.1 (0.0–2.6) 0 0
Other causes 1.1 (0.6–1.8) 2.5 (0.9–7.3) 0 0
Contributing causes of death for each group were
*860,
#55,
+104 and
{34 causes of death (i.e., death might have been attributed to more than one cause).
All rates were standardised for age (median age of 76.3 years), education, country of birth and smoking status.
doi:10.1371/journal.pone.0011266.t004
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published findings from the Nurses’ Health Study showed an
increase in the number of sudden cardiac deaths associated with
the use of antidepressants [47], a result that is consistent with our
observation of an excess of cardiovascular deaths amongst men
using antidepressants. Although these results cannot be considered
conclusive at this stage, as mortality information from long-term
randomized trials of antidepressants is not yet available, they do
highlight the need for further research and caution when
prescribing antidepressants to vulnerable older adults, particularly
when one considers that the efficacy of these drugs is modest
[48,49].
In summary, the results of our study indicate that mortality
hazard increases with the severity of depressive symptoms and that
treatment with antidepressants fails to reduce the mortality rate of
older men with persistent symptoms of depression.
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